ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

LIXT Lixte Biotechnology Holdings Inc

2.82
-0.0621 (-2.15%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Lixte Biotechnology Holdings Inc LIXT NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.0621 -2.15% 2.82 09:00:00
始値 安値 高値 終値 前日終値
3.00 2.8735 3.002 2.89 2.8821
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2504:25APSMixed Shelf Filing Gives Micro Cap Delayed Boost
2024/3/2804:35APSBiotech Steals The Show Following Pre-Clinical Data..
2024/3/2721:30GLOBENEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD..
2024/3/2121:30GLOBELIXTE Provides Update on Progress with LB-100 as a PP2A..
2024/2/2806:59EDGAR2Form 8-K - Current report
2024/2/2722:30GLOBEProfessor René Bernards to Present New Pre-Clinical Data on..
2024/2/2700:48EDGAR2Form 8-K - Current report
2024/2/2622:30GLOBELIXTE Biotechnology Enters into Exclusive Immune Oncology..
2024/1/2922:30GLOBEFirst Patient Dosed with LIXTE’s LB-100 and GSK’s..
2023/11/2907:21EDGAR2Form 8-K - Current report
2023/11/1404:28EDGAR2Form 8-K - Current report
2023/11/1322:30GLOBELIXTE Biotechnology Provides Update on Clinical Progress and..
2023/11/1007:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/10/1806:27EDGAR2Form 8-K - Current report
2023/10/1703:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/1621:30GLOBELIXTE, Netherlands Cancer Institute, and Oncode Institute to..
2023/10/1104:55EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/1104:47EDGAR2Form DEF 14A - Other definitive proxy statements
2023/10/0921:30GLOBELIXTE Biotechnology Holdings Announces the Passing of its..
2023/10/0609:39EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
2023/10/0609:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/0507:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/3005:05EDGAR2Form PRE 14A - Other preliminary proxy statements
2023/9/2719:15EDGAR2Form 8-K - Current report
2023/9/2719:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/2621:30GLOBELIXTE Appoints Bas van der Baan as President and Chief..
2023/9/2100:20EDGAR2Form 8-K - Current report
2023/9/2021:30GLOBELIXTE Biotechnology Announces a Supported Collaborative..
2023/8/1205:20EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/8/0921:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/7/2205:05EDGAR2Form 8-K - Current report
2023/7/2105:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2023/7/2105:05GLOBELIXTE Biotechnology Announces Closing of $3.5 Million..
2023/7/2100:45EDGAR2Form 8-K - Current report
2023/7/1821:00GLOBELIXTE Biotechnology Announces Pricing of $3.5 Million..
2023/7/1721:30GLOBEPreclinical Results of LIXTE Biotechnology’s Collaboration..
2023/7/0803:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/0723:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/0723:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/0723:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/6/2321:30GLOBELIXTE Biotechnology Holdings, Inc. Regains Compliance with..
2023/6/0721:30GLOBELIXTE Biotechnology and the Spanish Sarcoma Group Enroll..
2023/6/0301:30GLOBELIXTE Biotechnology Holdings, Inc. Announces 1-for-10..
2023/5/3021:30GLOBERecently Published Independent Research Reveals New..

最近閲覧した銘柄

Delayed Upgrade Clock